Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 14,611,466 shares of AKBA stock, worth $48.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,611,466
Previous 12,685,803
15.18%
Holding current value
$48.5 Million
Previous $24.4 Million
118.37%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AKBA
# of Institutions
169Shares Held
105MCall Options Held
134KPut Options Held
262K-
Black Rock Inc. New York, NY11.6MShares$38.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$26.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$20.2 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$19.1 Million20.26% of portfolio
-
Morgan Stanley New York, NY5.34MShares$17.7 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $610M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...